术前术后舒尼替尼治疗转移性肾细胞癌的II期研究:动态生物标志物与影像学变化
NeoSun单中心单臂II期试验纳入14例初治转移性肾细胞癌患者,术前接受12天舒尼替尼50mg每日一次,术后行4周用药2周停药周期直至进展。主要终点为客观缓解率(排除切除肾脏),58.3%(7/12)达部分或完全缓解(95%CI 27.7-84.8%),中位OS 33.7个月,中位PFS 15.7个月。术前舒尼替尼显著增加坏死,降低CD31、Ki67、循环VEGF-C和KTrans(均P<0.05)。
要点
- 术前舒尼替尼50mg每日一次×12天,58.3%患者达PR/CR,中位OS 33.7个月。
- 术前用药显著增加肿瘤坏死,降低CD31、Ki67、循环VEGF-C和KTrans(均P<0.05)。
- 基线血浆VEGF-C高表达者OS有改善趋势(P=0.02)。
核心结论
- 新辅助舒尼替尼治疗转移性肾细胞癌安全可行,并可有效探索转化生物标志物和影像学终点。
- 术前舒尼替尼可诱导肿瘤坏死并抑制增殖和血管生成相关标志物。
研究设计与样本
- NeoSun为单中心、单臂、单药II期试验(EudraCT 2005-004502-82)。
- 纳入14例初治转移性肾细胞癌患者,术前舒尼替尼50mg每日一次×12天,术后4周用药2周停药直至进展。
- 主要终点为排除切除肾脏的客观缓解率(RECIST),转化和影像学终点为探索性。
主要发现
- 58.3%(7/12)患者达部分或完全缓解(95%CI 27.7-84.8%)。
- 中位OS 33.7个月,中位PFS 15.7个月,达PR/CR者中位缓解持续时间8.7个月。
- 术前舒尼替尼显著增加坏死,降低CD31、Ki67、循环VEGF-C和KTrans(均P<0.05)。
- 基线血浆VEGF-C高表达者OS有改善趋势(P=0.02)。
- 术前舒尼替尼后影像学肿瘤体积缩小与基线实性成分高百分比相关(ρ=0.69,P=0.02),与基线坏死低百分比相关(系数=-0.51,P=0.03)。
临床怎么用
- 新辅助舒尼替尼方案未增加意外手术并发症、舒尼替尼相关毒性或手术延迟。
- 动态增强MRI的KTrans和循环VEGF-C等标志物可用于探索性评估抗血管生成治疗反应。
局限性
- 单中心、单臂、小样本II期探索性研究,转化和影像学终点仅为探索性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore translational biological and imaging biomarkers for sunitinib treatment before and after debulking nephrectomy in the NeoSun (European Union Drug Regulating Authorities Clinical Trials Database [EudraCT] number: 2005-004502-82) single-centre, single-arm, single-agent, Phase II trial. PATIENTS AND METHODS: Treatment-naïve patients with metastatic renal cell carcinoma (mRCC) received 50 mg once daily sunitinib for 12 days pre-surgically, then post-surgery on 4 week-on, 2 week-off, repeating 6-week cycles until disease progression in a single arm phase II trial. Structural and dynamic contrast-enhanced magnet resonance imaging (DCE-MRI) and research blood sampling were performed at baseline and after 12 days. Computed tomography imaging was performed at baseline and post-surgery then every two cycles. The primary endpoint was objective response rate (Response Evaluation Criteria In Solid Tumors [RECIST]) excluding the resected kidney. Secondary endpoints included changes in DCE-MRI of the tumour following pre-surgery sunitinib, overall survival (OS), progression-free survival (PFS), response duration, surgical morbidity/mortality, and toxicity. Translational and imaging endpoints were exploratory. RESULTS: A total of 14 patients received pre-surgery sunitinib, 71% (10/14) took the planned 12 doses. All underwent nephrectomy, and 13 recommenced sunitinib postoperatively. In all, 58.3% (seven of 12) of patients achieved partial or complete response (PR or CR) (95% confidence interval 27.7-84.8%). The median OS was 33.7 months and median PFS was 15.7 months. Amongst those achieving a PR or CR, the median response duration was 8.7 months. No unexpected surgical complications, sunitinib-related toxicities, or surgical delays occurred. Within the translational endpoints, pre-surgical sunitinib significantly increased necrosis, and reduced cluster of differentiation-31 (CD31), Ki67, circulating vascular endothelial growth factor-C (VEGF-C), and transfer constant (KTrans , measured using DCE-MRI; all P < 0.05). There was a trend for improved OS in patients with high baseline plasma VEGF-C expression (P = 0.02). Reduction in radiological tumour volume after pre-surgical sunitinib correlated with high percentage of solid tumour components at baseline (Spearman's coefficient ρ = 0.69, P = 0.02). Conversely, the percentage tumour volume reduction correlated with lower baseline percentage necrosis (coefficient = -0.51, P = 0.03). CONCLUSION: Neoadjuvant studies such as the NeoSun can safely and effectively explore translational biological and imaging endpoints.
引用
- Welsh SJ, Thompson N, Warren A, et al. Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib. BJU Int. 2021. PMID: 34549873. doi:10.1111/bju.15600
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。